{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:38:34Z","timestamp":1793032714163,"version":"4.5.0"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>Patients with CKD have a disproportionate burden of cardiovascular (CV) disease, and the majority die from CV causes before ever reaching kidney failure. Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease, cerebrovascular disease, and peripheral arterial disease, develops in CKD through the convergence of traditional risk factors and a distinct group of CKD-related, nontraditional mechanisms, including mineral and bone disorder with vascular calcification, chronic inflammation and oxidative stress, uremic toxicity, and an atherogenic dyslipidemia. CV and kidney disease interact in a bidirectional manner in which each accelerates the other. Reflecting this unique pathophysiology, the burden of ASCVD rises steeply as kidney function declines, reaching a several-fold higher risk of myocardial infarction, stroke, and peripheral arterial disease at the lowest eGFR and highest albuminuria. Nonetheless, ASCVD in CKD remains under-recognized and undertreated, owing partly to atypical clinical presentations, conventional risk-prediction tools that underestimate risk, and to the exclusion of patients with advanced CKD from most landmark CV trials. In this review, which focuses primarily on coronary artery disease in non\u2013dialysis-dependent CKD, we examine the epidemiology and key pathogenic mechanisms of ASCVD in this setting and appraise diagnostic and risk-prediction approaches together with their limitations, including contemporary CKD-adapted risk equations, cardiac biomarkers, and noninvasive imaging. We also summarize the current evidence for management, spanning lipid-lowering, antiplatelet, and BP therapies, newer cardiometabolic agents (including sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists), coronary revascularization, and lifestyle modification. Throughout, we highlight where high-quality, CKD-specific evidence is lacking, and we outline priority research gaps and emerging therapies directed at CKD-relevant pathways, such as inflammation. Recognizing and aggressively modifying CV risk in CKD, across both traditional and CKD-specific pathways, represents a substantial, and currently underrealized, opportunity to reduce morbidity and mortality in this high-risk population.<\/jats:p>","DOI":"10.2215\/cjn.0000001199","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:00:48Z","timestamp":1789401648000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Atherosclerotic Cardiovascular Disease in CKD"],"prefix":"10.2215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3987","authenticated-orcid":false,"given":"Simon","family":"Correa","sequence":"first","affiliation":[{"name":"Renal Division, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-7867","authenticated-orcid":false,"given":"Jonathan W.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Cardiovascular Disease Initiative, Broad Institute of Harvard University and the Massachusetts Institute of Technology, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-0533","authenticated-orcid":false,"given":"Finnian R.","family":"Mc Causland","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"10518","key":"B1-20261026","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the global burden of disease study 2023","volume":"406","year":"2025","journal-title":"Lancet."},{"issue":"4S","key":"B3-20261026","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"13","key":"B5-20261026","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA."},{"issue":"10","key":"B6-20261026","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1681\/ASN.2014101034","article-title":"Cause-specific deaths in non-dialysis-dependent CKD","volume":"26","author":"Navaneethan","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"17","key":"B7-20261026","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation."},{"issue":"9844","key":"B8-20261026","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"Lancet."},{"issue":"7","key":"B9-20261026","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"B10-20261026","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2011111115","article-title":"Cardiovascular disease in children with chronic kidney disease","volume":"23","author":"Mitsnefes","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B11-20261026","doi-asserted-by":"crossref","first-page":"sfae044","DOI":"10.1093\/ckj\/sfae044","article-title":"Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease","volume":"17","author":"Balafa","year":"2024","journal-title":"Clin Kidney J."},{"issue":"8","key":"B12-20261026","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic Renal Insufficiency Cohort (CRIC) study: baseline characteristics and associations with kidney function","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9854","key":"B13-20261026","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet."},{"issue":"6","key":"B14-20261026","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B15-20261026","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.ajkd.2018.11.010","article-title":"Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD","volume":"73","author":"Bajaj","year":"2019","journal-title":"Am J Kidney Dis."},{"issue":"9784","key":"B16-20261026","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"issue":"20","key":"B17-20261026","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/eurheartj\/ehx118","article-title":"Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease","volume":"38","author":"Zewinger","year":"2017","journal-title":"Eur Heart J."},{"issue":"9841","key":"B18-20261026","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet."},{"issue":"20","key":"B19-20261026","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med."},{"issue":"11","key":"B20-20261026","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int."},{"issue":"23","key":"B21-20261026","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","article-title":"Cardiovascular disease in chronic kidney disease","volume":"46","author":"Marx-Sch\u00fctt","year":"2025","journal-title":"Eur Heart J."},{"issue":"1","key":"B22-20261026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.119.043916","article-title":"Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment","volume":"141","author":"Bajaj","year":"2020","journal-title":"Circulation."},{"issue":"6","key":"B23-20261026","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCIMAGING.110.957761","article-title":"Coronary microvascular function in early chronic kidney disease","volume":"3","author":"Charytan","year":"2010","journal-title":"Circ Cardiovasc Imaging."},{"issue":"8","key":"B24-20261026","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.5858\/133.8.1309","article-title":"Arteriosclerosis: rethinking the current classification","volume":"133","author":"Fishbein","year":"2009","journal-title":"Arch Pathol Lab Med."},{"issue":"6","key":"B25-20261026","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ Res."},{"issue":"1","key":"B26-20261026","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2015.02.048","article-title":"Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference","volume":"241","author":"Mart\u00edn","year":"2015","journal-title":"Atherosclerosis."},{"issue":"5","key":"B27-20261026","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/CIRCRESAHA.116.305720","article-title":"Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease","volume":"116","author":"Huveneers","year":"2015","journal-title":"Circ Res."},{"issue":"3","key":"B28-20261026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10641963.2013.804541","article-title":"Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease","volume":"36","author":"Gauthier-Bastien","year":"2014","journal-title":"Clin Exp Hypertens."},{"issue":"1","key":"B29-20261026","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/HJH.0b013e32835b15bb","article-title":"Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences","volume":"31","author":"Shobeiri","year":"2013","journal-title":"J Hypertens."},{"issue":"2","key":"B30-20261026","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1681\/ASN.2013060635","article-title":"Serum calcification propensity predicts all-cause mortality in predialysis CKD","volume":"25","author":"Smith","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B31-20261026","doi-asserted-by":"crossref","first-page":"635.e1","DOI":"10.1016\/j.amjmed.2015.11.032","article-title":"Warfarin and vascular calcification","volume":"129","author":"Poterucha","year":"2016","journal-title":"Am J Med."},{"issue":"6","key":"B32-20261026","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2018111150","article-title":"A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD","volume":"30","author":"Sakaguchi","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B33-20261026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/embj.201284188","article-title":"FGF23 promotes renal calcium reabsorption through the TRPV5 channel","volume":"33","author":"Andrukhova","year":"2014","journal-title":"EMBO J."},{"issue":"11","key":"B34-20261026","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."},{"key":"B35-20261026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000346778","article-title":"Klotho and chronic kidney disease","volume":"180","author":"Hu","year":"2013","journal-title":"Contrib Nephrol"},{"issue":"1","key":"B36-20261026","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease","volume":"22","author":"Hu","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"6655","key":"B37-20261026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature."},{"issue":"10","key":"B38-20261026","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/ndt\/gfx376","article-title":"Albumin downregulates Klotho in tubular cells","volume":"33","author":"Fernandez-Fernandez","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"18","key":"B39-20261026","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.jacc.2018.08.2147","article-title":"Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC macrophage in CVD series (part 2)","volume":"72","author":"Moore","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B40-20261026","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.atherosclerosis.2015.08.012","article-title":"Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses","volume":"242","author":"Navratil","year":"2015","journal-title":"Atherosclerosis."},{"key":"B41-20261026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.10.016","article-title":"Electronegative L5-LDL induces the production of G-CSF and GM-CSF in human macrophages through LOX-1 involving NF-\u03baB and ERK2 activation","volume":"267","author":"Yang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"8","key":"B42-20261026","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jacc.2011.11.019","article-title":"Translational studies of lipoprotein-associated phospholipase A2 in inflammation and atherosclerosis","volume":"59","author":"Ferguson","year":"2012","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"B43-20261026","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jacc.2005.11.086","article-title":"Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events","volume":"47","author":"Sangiorgi","year":"2006","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"B44-20261026","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1038\/s41598-019-46824-2","article-title":"Activation of KEAP1\/NRF2\/P62 signaling alleviates high phosphate-induced calcification of vascular smooth muscle cells by suppressing reactive oxygen species production","volume":"9","author":"Wei","year":"2019","journal-title":"Sci Rep."},{"issue":"16","key":"B45-20261026","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.3390\/ijms26167938","article-title":"The non-traditional cardiovascular culprits in chronic kidney disease: mineral imbalance and uremic toxin accumulation","volume":"26","author":"Lu","year":"2025","journal-title":"Int J Mol Sci."},{"issue":"1","key":"B46-20261026","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/0886022X.2020.1845731","article-title":"Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease","volume":"42","author":"Wang","year":"2020","journal-title":"Ren Fail."},{"issue":"1","key":"B47-20261026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/CIRCULATIONAHA.118.034588","article-title":"Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-Notch signaling","volume":"139","author":"Nakano","year":"2019","journal-title":"Circulation."},{"issue":"10","key":"B48-20261026","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/sj.ki.5000340","article-title":"Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells","volume":"69","author":"Yamamoto","year":"2006","journal-title":"Kidney Int."},{"issue":"2","key":"B49-20261026","doi-asserted-by":"crossref","first-page":"C126","DOI":"10.1152\/ajpcell.00329.2011","article-title":"Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress","volume":"303","author":"Muteliefu","year":"2012","journal-title":"Am J Physiol Cell Physiol."},{"issue":"3","key":"B50-20261026","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11684-016-0463-x","article-title":"p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells","volume":"10","author":"Han","year":"2016","journal-title":"Front Med."},{"issue":"4","key":"B51-20261026","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/jcm14041051","article-title":"Asymmetric dimethylarginine (ADMA) as a novel risk factor for progression of coronary artery calcification in patients with chronic kidney disease","volume":"14","author":"Kobayashi","year":"2025","journal-title":"J Clin Med."},{"issue":"12","key":"B52-20261026","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5551\/jat.14035","article-title":"Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages","volume":"20","author":"Apostolov","year":"2013","journal-title":"J Atheroscler Thromb."},{"issue":"5","key":"B53-20261026","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2014.04.034","article-title":"Protein carbamylation in kidney disease: pathogenesis and clinical implications","volume":"64","author":"Kalim","year":"2014","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"B54-20261026","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41581-023-00747-4","article-title":"Diagnosis of cardiovascular disease in patients with chronic kidney disease","volume":"19","author":"Zoccali","year":"2023","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"B55-20261026","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham heart study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation."},{"issue":"25 suppl 2","key":"B56-20261026","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation."},{"issue":"2","key":"B57-20261026","doi-asserted-by":"crossref","first-page":"c171","DOI":"10.1159\/000325669","article-title":"Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction","volume":"119","author":"Chang","year":"2011","journal-title":"Nephron Clin Pract."},{"issue":"11","key":"B58-20261026","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation."},{"key":"B59-20261026","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"6","key":"B60-20261026","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation."},{"issue":"24","key":"B61-20261026","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation."},{"issue":"12","key":"B62-20261026","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jama.2024.12537","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations","volume":"332","author":"Diao","year":"2024","journal-title":"JAMA."},{"issue":"1","key":"B63-20261026","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.ajkd.2025.01.012","article-title":"Cardiovascular disease risk estimates in the US CKD population using the PREVENT equation","volume":"86","author":"Walther","year":"2025","journal-title":"Am J Kidney Dis."},{"issue":"19","key":"B64-20261026","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"B65-20261026","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1681\/ASN.2021060747","article-title":"Risk prediction models for atherosclerotic cardiovascular disease in patients with chronic kidney disease: the CRIC study","volume":"33","author":"Bundy","year":"2022","journal-title":"J Am Soc Nephrol."},{"key":"B66-20261026","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"B67-20261026","article-title":"Cardiovascular risk assessment tools in CKD","author":"Zoccali","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B68-20261026","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.117.029986","article-title":"Origin of cardiac troponin T elevations in chronic kidney disease","volume":"136","author":"van der Linden","year":"2017","journal-title":"Circulation."},{"issue":"8","key":"B69-20261026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3949\/ccjm.90a.23012","article-title":"Evaluating troponin elevation in patients with chronic kidney disease and suspected acute coronary syndrome","volume":"90","author":"Braghieri","year":"2023","journal-title":"Cleve Clin J Med."},{"key":"B70-20261026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2369-14-229","article-title":"Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the Chronic Renal Insufficiency Cohort (CRIC)","volume":"14","author":"Dubin","year":"2013","journal-title":"BMC Nephrol"},{"key":"B71-20261026","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cca.2020.01.027","article-title":"The 99th percentile upper reference limit for the 5th generation cardiac troponin T assay in the United States","volume":"504","author":"Fitzgerald","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"2","key":"B72-20261026","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1681\/ASN.2017030341","article-title":"Renal dysfunction influences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I","volume":"29","author":"Gunsolus","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B73-20261026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2024.08.009","article-title":"Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction","volume":"13","author":"Neuen","year":"2025","journal-title":"JACC Heart Fail."},{"issue":"3","key":"B74-20261026","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2215\/CJN.03600414","article-title":"Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD","volume":"10","author":"Colbert","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B75-20261026","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the German chronic kidney disease study","volume":"296","author":"Gruber","year":"2024","journal-title":"J Intern Med."},{"issue":"13","key":"B76-20261026","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/CIRCULATIONAHA.107.696765","article-title":"Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction","volume":"116","author":"Herzog","year":"2007","journal-title":"Circulation."},{"issue":"3","key":"B77-20261026","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.ajkd.2005.11.017","article-title":"Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective","volume":"47","author":"Sosnov","year":"2006","journal-title":"Am J Kidney Dis."},{"issue":"10","key":"B78-20261026","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1681\/ASN.V7102044","article-title":"Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis","volume":"7","author":"de Lemos","year":"1996","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B79-20261026","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/ndt\/gfi005","article-title":"Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates","volume":"20","author":"Sharma","year":"2005","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B80-20261026","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2010.11.018","article-title":"Cardiac testing for coronary artery disease in potential kidney transplant recipients: a systematic review of test accuracy studies","volume":"57","author":"Wang","year":"2011","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B81-20261026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1573403X10666140214122234","article-title":"Coronary artery disease in patients with chronic kidney disease: a clinical update","volume":"9","author":"Cai","year":"2013","journal-title":"Curr Cardiol Rev."},{"issue":"3","key":"B82-20261026","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jcmg.2020.05.035","article-title":"Cardiac imaging for coronary heart disease risk stratification in chronic kidney disease","volume":"14","author":"Dilsizian","year":"2021","journal-title":"JACC Cardiovasc Imaging."},{"issue":"1","key":"B83-20261026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000510402","article-title":"Coronary computed tomography angiography in diagnosing obstructive coronary artery disease in patients with advanced chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Cheng","year":"2021","journal-title":"Cardiorenal Med."},{"issue":"1","key":"B84-20261026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12968-020-00634-y","article-title":"The reliability and feasibility of non-contrast adenosine stress cardiovascular magnetic resonance T1 mapping in patients on haemodialysis","volume":"22","author":"Poli","year":"2020","journal-title":"J Cardiovasc Magn Reson."},{"issue":"34","key":"B85-20261026","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"issue":"3","key":"B86-20261026","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.HYP.0000087889.60760.87","article-title":"Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing","volume":"42","author":"De Lima","year":"2003","journal-title":"Hypertension."},{"issue":"4","key":"B87-20261026","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"issue":"10","key":"B88-20261026","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B89-20261026","doi-asserted-by":"crossref","first-page":"120563","DOI":"10.1016\/j.atherosclerosis.2025.120563","article-title":"Lipid lowering therapies in chronic kidney disease: a call to action","volume":"411","author":"Maz\u00f3n-Ruiz","year":"2025","journal-title":"Atherosclerosis"},{"issue":"9","key":"B90-20261026","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.2022020135","article-title":"Association of rosuvastatin use with risk of hematuria and proteinuria","volume":"33","author":"Shin","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"17","key":"B91-20261026","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation."},{"issue":"10","key":"B92-20261026","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1681\/ASN.2016090957","article-title":"Benefit of ezetimibe added to simvastatin in reduced kidney function","volume":"28","author":"Stanifer","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"23","key":"B93-20261026","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"B94-20261026","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1681\/ASN.0000001006","article-title":"Inclisiran in patients with CKD: post hoc pooled analysis of three phase 3 trials","volume":"37","author":"Landmesser","year":"2026","journal-title":"J Am Soc Nephrol."},{"issue":"15","key":"B95-20261026","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"B96-20261026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med."},{"issue":"22","key":"B97-20261026","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: reduce-it renal","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation."},{"issue":"6","key":"B98-20261026","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int."},{"issue":"15","key":"B99-20261026","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y(12)-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation."},{"issue":"10","key":"B100-20261026","first-page":"e212","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension."},{"issue":"23","key":"B101-20261026","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation."},{"issue":"24","key":"B102-20261026","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"B103-20261026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"15","key":"B104-20261026","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"B105-20261026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"B106-20261026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"suppl 1","key":"B107-20261026","first-page":"S216","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care."},{"issue":"6","key":"B108-20261026","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"issue":"23","key":"B109-20261026","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"17","key":"B110-20261026","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med."},{"issue":"7","key":"B111-20261026","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jacc.2018.05.057","article-title":"Left main revascularization with PCI or CABG in patients with chronic kidney disease: EXCEL trial","volume":"72","author":"Giustino","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B112-20261026","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.kint.2016.03.033","article-title":"Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease","volume":"90","author":"Charytan","year":"2016","journal-title":"Kidney Int."},{"issue":"9","key":"B113-20261026","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation."},{"issue":"3","key":"B114-20261026","doi-asserted-by":"crossref","first-page":"e240427","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review","volume":"7","author":"Colombijn","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"8","key":"B115-20261026","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med."},{"issue":"1","key":"B116-20261026","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, design, and baseline clinical characteristics of the ziltivekimab cardiovascular outcomes trial: interleukin-6 inhibition and atherosclerotic event rate reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:00:28Z","timestamp":1793030428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001199"}},"subtitle":["Contemporary Insights into Pathogenesis, Diagnosis, and Management"],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":114,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001199","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}